HUTCHMED (China) Limited announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors.
[HUTCHMED (China) Limited]
